Preexisting and de novo humoral immunity to SARS-CoV-2 in humans.

Autor: Ng KW; Retroviral Immunology, The Francis Crick Institute, London NW1 1AT, UK., Faulkner N; Retroviral Immunology, The Francis Crick Institute, London NW1 1AT, UK., Cornish GH; Retroviral Immunology, The Francis Crick Institute, London NW1 1AT, UK., Rosa A; Chromatin Structure and Mobile DNA Laboratory, The Francis Crick Institute, London NW1 1AT, UK., Harvey R; Worldwide Influenza Centre, The Francis Crick Institute, London NW1 1AT, UK., Hussain S; Worldwide Influenza Centre, The Francis Crick Institute, London NW1 1AT, UK., Ulferts R; Cell Biology of Infection Laboratory, The Francis Crick Institute, London NW1 1AT, UK., Earl C; Signalling and Structural Biology Laboratory, The Francis Crick Institute, London NW1 1AT, UK., Wrobel AG; Structural Biology of Disease Processes Laboratory, The Francis Crick Institute, London NW1 1AT, UK., Benton DJ; Structural Biology of Disease Processes Laboratory, The Francis Crick Institute, London NW1 1AT, UK., Roustan C; Structural Biology STP, The Francis Crick Institute, London NW1 1AT, UK., Bolland W; Retroviral Immunology, The Francis Crick Institute, London NW1 1AT, UK., Thompson R; Retroviral Immunology, The Francis Crick Institute, London NW1 1AT, UK., Agua-Doce A; Flow Cytometry STP, The Francis Crick Institute, London NW1 1AT, UK., Hobson P; Flow Cytometry STP, The Francis Crick Institute, London NW1 1AT, UK., Heaney J; University College London Hospitals (UCLH) NHS Trust, London NW1 2BU, UK., Rickman H; University College London Hospitals (UCLH) NHS Trust, London NW1 2BU, UK., Paraskevopoulou S; University College London Hospitals (UCLH) NHS Trust, London NW1 2BU, UK., Houlihan CF; University College London Hospitals (UCLH) NHS Trust, London NW1 2BU, UK.; Division of Infection and Immunity, University College London (UCL), London WC1E 6BT, UK., Thomson K; University College London Hospitals (UCLH) NHS Trust, London NW1 2BU, UK., Sanchez E; University College London Hospitals (UCLH) NHS Trust, London NW1 2BU, UK., Shin GY; University College London Hospitals (UCLH) NHS Trust, London NW1 2BU, UK., Spyer MJ; University College London Hospitals (UCLH) NHS Trust, London NW1 2BU, UK.; Department of Population, Policy and Practice, Great Ormond Street Institute for Child Health (ICH), UCL, London WC1N 1EH, UK., Joshi D; Peptide Chemistry, The Francis Crick Institute, London NW1 1AT, UK., O'Reilly N; Peptide Chemistry, The Francis Crick Institute, London NW1 1AT, UK., Walker PA; Structural Biology STP, The Francis Crick Institute, London NW1 1AT, UK., Kjaer S; Structural Biology STP, The Francis Crick Institute, London NW1 1AT, UK., Riddell A; Flow Cytometry STP, The Francis Crick Institute, London NW1 1AT, UK., Moore C; Public Health Wales, University Hospital of Wales, Cardiff CF14 4XW, UK., Jebson BR; Centre for Adolescent Rheumatology Versus Arthritis at UCL, UCLH, Great Ormond Street Hospital (GOSH), London WC1N 3JH, UK.; UCL Great Ormond Street Institute for Child Health (ICH), UCL, London WC1N 1EH, UK., Wilkinson M; Centre for Adolescent Rheumatology Versus Arthritis at UCL, UCLH, Great Ormond Street Hospital (GOSH), London WC1N 3JH, UK.; UCL Great Ormond Street Institute for Child Health (ICH), UCL, London WC1N 1EH, UK., Marshall LR; Centre for Adolescent Rheumatology Versus Arthritis at UCL, UCLH, Great Ormond Street Hospital (GOSH), London WC1N 3JH, UK.; UCL Great Ormond Street Institute for Child Health (ICH), UCL, London WC1N 1EH, UK., Rosser EC; Centre for Adolescent Rheumatology Versus Arthritis at UCL, UCLH, Great Ormond Street Hospital (GOSH), London WC1N 3JH, UK.; Centre for Rheumatology Research, Division of Medicine, UCL, London, WC1E 6BT, UK., Radziszewska A; Centre for Adolescent Rheumatology Versus Arthritis at UCL, UCLH, Great Ormond Street Hospital (GOSH), London WC1N 3JH, UK.; Centre for Rheumatology Research, Division of Medicine, UCL, London, WC1E 6BT, UK., Peckham H; Centre for Adolescent Rheumatology Versus Arthritis at UCL, UCLH, Great Ormond Street Hospital (GOSH), London WC1N 3JH, UK.; Centre for Rheumatology Research, Division of Medicine, UCL, London, WC1E 6BT, UK., Ciurtin C; Centre for Adolescent Rheumatology Versus Arthritis at UCL, UCLH, Great Ormond Street Hospital (GOSH), London WC1N 3JH, UK.; Centre for Rheumatology Research, Division of Medicine, UCL, London, WC1E 6BT, UK., Wedderburn LR; Centre for Adolescent Rheumatology Versus Arthritis at UCL, UCLH, Great Ormond Street Hospital (GOSH), London WC1N 3JH, UK.; UCL Great Ormond Street Institute for Child Health (ICH), UCL, London WC1N 1EH, UK., Beale R; Cell Biology of Infection Laboratory, The Francis Crick Institute, London NW1 1AT, UK., Swanton C; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London NW1 1AT, UK., Gandhi S; Neurodegeneration Biology Laboratory, The Francis Crick Institute, London NW1 1AT, UK., Stockinger B; AhRimmunity Laboratory, The Francis Crick Institute, London NW1 1AT, UK., McCauley J; Worldwide Influenza Centre, The Francis Crick Institute, London NW1 1AT, UK., Gamblin SJ; Structural Biology of Disease Processes Laboratory, The Francis Crick Institute, London NW1 1AT, UK., McCoy LE; Division of Infection and Immunity, University College London (UCL), London WC1E 6BT, UK. george.kassiotis@crick.ac.uk e.nastouli@ucl.ac.uk peter.cherepanov@crick.ac.uk l.mccoy@ucl.ac.uk., Cherepanov P; Chromatin Structure and Mobile DNA Laboratory, The Francis Crick Institute, London NW1 1AT, UK. george.kassiotis@crick.ac.uk e.nastouli@ucl.ac.uk peter.cherepanov@crick.ac.uk l.mccoy@ucl.ac.uk., Nastouli E; University College London Hospitals (UCLH) NHS Trust, London NW1 2BU, UK. george.kassiotis@crick.ac.uk e.nastouli@ucl.ac.uk peter.cherepanov@crick.ac.uk l.mccoy@ucl.ac.uk.; Department of Population, Policy and Practice, Great Ormond Street Institute for Child Health (ICH), UCL, London WC1N 1EH, UK., Kassiotis G; Retroviral Immunology, The Francis Crick Institute, London NW1 1AT, UK. george.kassiotis@crick.ac.uk e.nastouli@ucl.ac.uk peter.cherepanov@crick.ac.uk l.mccoy@ucl.ac.uk.; Department of Medicine, Faculty of Medicine, Imperial College London, London W2 1PG, UK.
Jazyk: angličtina
Zdroj: Science (New York, N.Y.) [Science] 2020 Dec 11; Vol. 370 (6522), pp. 1339-1343. Date of Electronic Publication: 2020 Nov 06.
DOI: 10.1126/science.abe1107
Abstrakt: Zoonotic introduction of novel coronaviruses may encounter preexisting immunity in humans. Using diverse assays for antibodies recognizing SARS-CoV-2 proteins, we detected preexisting humoral immunity. SARS-CoV-2 spike glycoprotein (S)-reactive antibodies were detectable using a flow cytometry-based method in SARS-CoV-2-uninfected individuals and were particularly prevalent in children and adolescents. They were predominantly of the immunoglobulin G (IgG) class and targeted the S2 subunit. By contrast, SARS-CoV-2 infection induced higher titers of SARS-CoV-2 S-reactive IgG antibodies targeting both the S1 and S2 subunits, and concomitant IgM and IgA antibodies, lasting throughout the observation period. SARS-CoV-2-uninfected donor sera exhibited specific neutralizing activity against SARS-CoV-2 and SARS-CoV-2 S pseudotypes. Distinguishing preexisting and de novo immunity will be critical for our understanding of susceptibility to and the natural course of SARS-CoV-2 infection.
(Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje